Tobacco Use Disorder Clinical Trial
Official title:
Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders
This research aims to identify efficacious strategies for treating tobacco dependence among
adolescent smokers with co-occurring psychiatric disorders. Adolescent smoking remains a
significant public health issue with 23% of high school students reporting smoking a
cigarette in the past month1. Smoking rates are two to four times higher among adolescents
with psychiatric disorders such as attention deficit disorders, conduct disorder,
depression, anxiety disorders, and alcohol and illicit drug dependencies2-4.
Empirical investigations of adolescent tobacco treatment interventions number less than 50
with many of the studies criticized for methodological problems (i.e., follow up < 6 months,
poor retention, lack of control or comparison groups)2,5, 6. There have been no unequivocal
successes; however, promising interventions include stage-based, cognitive behavioral (CBT),
and multicomponent treatments2, 7. Additionally, the nicotine patch is well tolerated and
safe among adolescents8 and rarely abused9. Less than a third of adolescent tobacco users
report intention to quit in the near future2, 10, 11; thus, it seems critical that cessation
interventions for this complex group be designed to assist smokers at all stages of
readiness through the quitting process. A stepped care approach has the potential of
matching more intensive services to those ready for and in need of greater treatment.
Interventions delivered in health care settings have the appeal of broad reach.
The primary specific aims of this research are to evaluate, in a randomized clinical trial
(N=160), the efficacy of a stepped care intervention for treating smoking among adolescents
recruited from outpatient psychiatry settings. To our knowledge, this would be the first
study to examine outpatient psychiatry settings for treating tobacco dependence in
adolescents. The stepped care intervention combines expert-system contacts, individual CBT
sessions, and 12-weeks of nicotine replacement therapy (NRT).
Status | Completed |
Enrollment | 60 |
Est. completion date | April 2010 |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 13 Years to 25 Years |
Eligibility |
Inclusion Criteria: - receiving active outpatient psychiatric care - report smoking at least 1 cigarette in the previous 30 days and at least 100 cigarettes in their lifetime - Other inclusion criteria are: no plan to relocate outside of the greater San Francisco Bay Area in the next 12 months and telephone access for scheduling follow up assessments. Exclusion Criteria: - cognitive impairment precluding ability to participate - non-English speaking - currently engaged in tobacco treatment - Recruitment of acutely psychotic, manic, or hostile patients will be delayed until there is significant reduction of these symptoms and patients are able to assent to study participation |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Edgewood Center for Children and Families | San Bruno | California |
United States | UCSF Langley Porter Psychiatric Institute | San Francisco | California |
United States | San Mateo County Mental Health | San Mateo | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 7 day point prevalence of cigarette abstinence | 3, 6, 12 months post baseline | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02432066 -
Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions
|
Phase 2 | |
Completed |
NCT03960138 -
Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Completed |
NCT04646668 -
Comparative Abuse Liability Among African American and White Smokers
|
N/A | |
Completed |
NCT02560324 -
Effect of Ramelteon on Smoking Abstinence
|
Phase 2 | |
Completed |
NCT02347605 -
Medicinal Nicotine for Preventing Cue Induced Craving
|
N/A | |
Completed |
NCT01570595 -
Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
|
Phase 1/Phase 2 | |
Completed |
NCT01625767 -
Tobacco Approach Avoidance Training for Adolescent Smokers-1
|
Phase 2 | |
Terminated |
NCT01800500 -
Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers
|
N/A | |
Completed |
NCT01442753 -
Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth
|
N/A | |
Completed |
NCT01428310 -
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
|
Phase 1 | |
Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
Completed |
NCT01337817 -
A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers
|
Phase 1 | |
Completed |
NCT00967005 -
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
|
Phase 2 | |
Active, not recruiting |
NCT00751660 -
Screening Methods in Finding Lung Cancer Early in Current or Former Smokers
|
N/A | |
Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
Completed |
NCT00664261 -
Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking
|
N/A | |
Completed |
NCT00158145 -
Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2
|
Phase 2 | |
Completed |
NCT00158158 -
Effectiveness of Reducing Smoking in Facilitating Smoking Cessation in Adolescents - 2
|
Phase 2/Phase 3 | |
Completed |
NCT01213524 -
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
|
Phase 2 |